Evaluation of effectiveness of orlistat in complexed obesity treatment in teenagers with metabolic syndrome

Q3 Medicine

Obesity and Metabolism Pub Date : 2011-12-15 DOI:10.14341/2071-8713-5302

G. Mel’nichenko, V. Peterkova, L. Savel'eva, N. Zubkova

{"title":"Evaluation of effectiveness of orlistat in complexed obesity treatment in teenagers with metabolic syndrome","authors":"G. Mel’nichenko, V. Peterkova, L. Savel'eva, N. Zubkova","doi":"10.14341/2071-8713-5302","DOIUrl":null,"url":null,"abstract":"An open, comparative, randomized study of orlistat in the combined treatment of obesity in adolescents with metabolic syndrome\n(IIIb phase) was held. Objective: to evaluate the efficacy and safety of the orlistat in adolescents 12-17 years with high risk of cardiovascular\ndisease and type 2 diabetes. The study included 60 adolescents with obesity and metabolic syndrome. The main group (n=30)\nfollowed a hypocaloric diet and aerobic exercises and took orlistat 120 mg 3 times daily with meals, the control (n=30) group was only\non the non-drug therapy. During the study the anthropometric parameters, lipid, carbohydrate metabolism, blood pressure were evaluated.\nAll comparisons were performed as two-way, with the critical level of significance ≤ 0,05. Results: After 6 months therapy of orlistat\n68% of adolescents achieved clinically meaningful weight loss, that led to the improvement of metabolic parameters. On therapy body\nfat decreased by -6600.00 g [-7912.00, -2350.00] in the control group, respectively -2235.50 g [-4700, 00; 667.00] (p=0.011). Orlistat\nwas well tolerated by patients. Most adverse events (9 of 13 in the intervention group) were mild and can be attributed to the expected\nadverse reactions. Conclusion: The study demonstrated clinically significant efficacy (compared with the control group), combined with\ngood safety records of its use in adolescents 12-17 years old with obesity and metabolic disorders.","PeriodicalId":37832,"journal":{"name":"Obesity and Metabolism","volume":"8 1","pages":"36-42"},"PeriodicalIF":0.0000,"publicationDate":"2011-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/2071-8713-5302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

An open, comparative, randomized study of orlistat in the combined treatment of obesity in adolescents with metabolic syndrome (IIIb phase) was held. Objective: to evaluate the efficacy and safety of the orlistat in adolescents 12-17 years with high risk of cardiovascular disease and type 2 diabetes. The study included 60 adolescents with obesity and metabolic syndrome. The main group (n=30) followed a hypocaloric diet and aerobic exercises and took orlistat 120 mg 3 times daily with meals, the control (n=30) group was only on the non-drug therapy. During the study the anthropometric parameters, lipid, carbohydrate metabolism, blood pressure were evaluated. All comparisons were performed as two-way, with the critical level of significance ≤ 0,05. Results: After 6 months therapy of orlistat 68% of adolescents achieved clinically meaningful weight loss, that led to the improvement of metabolic parameters. On therapy body fat decreased by -6600.00 g [-7912.00, -2350.00] in the control group, respectively -2235.50 g [-4700, 00; 667.00] (p=0.011). Orlistat was well tolerated by patients. Most adverse events (9 of 13 in the intervention group) were mild and can be attributed to the expected adverse reactions. Conclusion: The study demonstrated clinically significant efficacy (compared with the control group), combined with good safety records of its use in adolescents 12-17 years old with obesity and metabolic disorders.

查看原文本刊更多论文

奥利司他治疗青少年代谢综合征复杂肥胖的疗效评价

一项开放、比较、随机研究奥利司他联合治疗青少年代谢综合征(IIIb期)肥胖。目的:评价奥利司他在12-17岁心血管疾病和2型糖尿病高危青少年中的疗效和安全性。该研究包括60名患有肥胖和代谢综合征的青少年。主要组(n=30)在低热量饮食和有氧运动的基础上，口服奥利司他120 mg，每日3次，随餐服用，对照组(n=30)只进行非药物治疗。在研究期间，测量了人体测量参数、脂质、碳水化合物代谢和血压。所有比较均采用双向比较，显著性临界水平≤0.05。结果:经6个月奥利司他治疗后，68%的青少年实现了有临床意义的体重减轻，代谢参数得到改善。治疗后，对照组体脂下降-6600.00 g[-7912.00， -2350.00]，分别为-2235.50 g [- 4700000];667.00 (p = 0.011)。奥利司他在患者中耐受性良好。大多数不良事件(干预组13例中有9例)是轻微的，可归因于预期的不良反应。结论:该研究显示出临床显著的疗效(与对照组相比)，并结合其在12-17岁肥胖和代谢紊乱青少年中使用的良好安全性记录。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity and Metabolism Medicine-Internal Medicine

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Journal "Obesity and Metabolism" is a multidisciplinary forum for clinical and applied research in the field of biochemistry, physiology, pathophysiology, genetics, nutrition, as well as molecular, metabolic, psychological and epidemiological aspects of obesity and metabolism. The main subject "Metabolism" reviewed in the journal, includes fat, carbohydrate, protein, bone, fluid and electrolyte and other types of metabolism in the spectrum of pathology of the endocrine system. The priority direction of Journal "Obesity and Metabolism" is publishing modern high-quality original research on the effectiveness of new and existing treatments in any aspect of metabolic and endocrine diseases. Pre-clinical pharmacology, pharmacokinetics studies, meta-analyzes, addressed to drug safety and tolerance are also welcome for publication in the journal "Obesity and metabolism." Journal "Obesity and Metabolism" announces review articles that are balanced, clear and offer the reader a modern and critical analysis of the literature on the subject of the magazine. Case reports, and lecture materials are also published for highlighting for practitioners new approaches to diagnosis and treatment of patients with metabolic disorders and obesity.